Metrics & Benchmarks

>

Latest News

EMBARK Trial Shows Xtandi Combination Demonstrates Significant Overall Response in Non-Metastatic Hormone-Sensitive Prostate Cancer
EMBARK Trial Shows Xtandi Combination Demonstrates Significant Overall Response in Non-Metastatic Hormone-Sensitive Prostate Cancer

July 10th 2025

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a statistically significant and clinically meaningful overall survival benefit in men with non-metastatic hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Credit: steph photographies | stock.adobe.com. The KEYNOTE-689 trial demonstrated that adding neoadjuvant and adjuvant Keytruda to standard-of-care (SOC) radiotherapy significantly improved event-free survival in patients with resectable, locally advanced HNSCC, with benefits observed across PD-L1 CPS ≥10, ≥1, and intent-to-treat populations.
KEYNOTE-689 Trial Shows Perioperative Keytruda Significantly Improves Survival in Resectable Locally Advanced HNSCC

July 9th 2025

BlueRock Begins First Human Trial of iPSC Cell Therapy for Primary Photoreceptor Diseases
BlueRock Begins First Human Trial of iPSC Cell Therapy for Primary Photoreceptor Diseases

July 8th 2025

Credit: Daniel Krasoń | stock.adobe.com. Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity
REDEFINE 1 Trial Finds Cagrilintide–Semaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients

July 1st 2025

Credit: Crystal light | stock.adobe.com. Human kidneys anatomy structure, kidney disease.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy

June 30th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.